Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA-Cancer J Clin. 2013;63(1):11. doi:10.3322/caac.2133223335087
   PubMed Web of Science ®Google Scholar
• Rossi A, Maione P, Colantuoni G, et al. Treatment of small cell lung cancer in the elderly. Oncologist. 2005;42(1):399–411. doi:10.1634/theoncologist.10-6-399
   Google Scholar
• Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000;83(1):8–15. doi:10.1054/bjoc.2000.116410883661
   PubMed Web of Science ®Google Scholar
• Eckert F, Muller AC. SCLC extensive disease–treatment guidance by extent or/and biology of response? Radiat Oncol. 2008;3:33. doi:10.1186/1748-717X-3-3318831728
   PubMed Web of Science ®Google Scholar
• Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized Phase III trial with 5 years’ follow-up. J Clin Oncol. 2002;20(24):4665–4672. doi:10.1200/JCO.2002.12.11112488411
   PubMed Web of Science ®Google Scholar
• Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now?-a review. Transl Lung Cancer Res. 2016;5(1):26–38. doi:10.3978/j.issn.2218-6751.2016.01.1326958491
   PubMed Web of Science ®Google Scholar
• Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009;14(10):986–994. doi:10.1634/theoncologist.2009-002619819917
   PubMed Web of Science ®Google Scholar
• Slotman BJ, Faivre-Finn C, Tinteren HV, et al. International multicenter randomized study on thoracic radiation therapy (RT) in extensive stage small cell lung cancer (ES-SCLC): patterns of disease recurrence. Int J Radiat Oncol Bio Phys. 2014;90(1):S3–S4. doi:10.1016/j.ijrobp.2014.06.023
   Google Scholar
• Slotman BJ, Faivrefinn C, Van Tinteren H, et al. Randomized trial on thoracic radiotherapy (TRT) in extensive-stage small cell lung cancer. J Clin Oncol. 2014;32(Suppl):abstr 7502. doi:10.1200/jco.2014.32.15_suppl.7502
   Google Scholar
• Eskandar A, Ahmed A, Daughtey M, Kenderian S, Mahdi F, Khan A. Racial and sex differences in presentation and outcomes of small cell lung cancer in the United States: 1973 to 2010. Chest. 2015;147(4):e164–e165. doi:10.1378/chest.14-305125846546
   PubMed Web of Science ®Google Scholar
• Liu TX, Dong M, Zhang YM. Therapeutic effect of three dimensional conformal radiotherapy in patients aged 65 years and older with non-small cell lung cancer. J Chin Lung. 2006;9(5):462–464. doi:10.3779/j.issn.1009-3419.2006.05.16
   Google Scholar
• Chen X, Fang J, Nie J, et al. Multivariate analysis of prognostic factors in the elderly patients with small cell lung cancer a study of 160 patients. Clin J of Lung Cancer. 2014;17(1):15–23. doi:10.3779/j.issn.1009-3419.2014.01.03
   Google Scholar
• Xu LM, Cheng C, Kang M, et al. Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer. Sci Rep. 2017;7(1):9255. doi:10.1038/s41598-017-09775-028835666
   PubMedGoogle Scholar
• Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593–a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(8):2114–2122. doi:10.1200/JCO.2001.19.8.211411304763
   PubMed Web of Science ®Google Scholar
• Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol. 1993;11(7):1230–1240. doi:10.1200/JCO.1993.11.7.12308391065
   PubMedGoogle Scholar
• Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol. 1996;14(8):2337–2344. doi:10.1200/JCO.1996.14.8.23378708726
   PubMed Web of Science ®Google Scholar
• Lara PJ, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27(15):2530–2535. doi:10.1200/JCO.2008.20.106119349543
   PubMed Web of Science ®Google Scholar
• Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85–91. doi:10.1056/NEJMoa00303411784874
   PubMed Web of Science ®Google Scholar
• Niell HB, Herndon JN, Miller AA, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and Leukemia Group B Trial 9732. J Clin Oncol. 2005;23(16):3752–3759. doi:10.1200/JCO.2005.09.07115923572
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Kadota K, Huberman K, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138–1145. doi:10.1158/1078-0432.CCR-11-205922228633
   PubMed Web of Science ®Google Scholar
• Von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012–4019. doi:10.1200/JCO.2013.54.539225385727
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078–2092. doi:10.1056/NEJMoa180100529658856
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X27979383
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa150764326412456
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-726712084
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa180906430280641
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Pennell NA, Fidler MJ, et al. Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC). J Thorac Oncol. 2018;13(9):1393–1399. doi:10.1016/j.jtho.2018.05.00229775808
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. doi:10.1200/JCO.2016.67.660127458307
   PubMed Web of Science ®Google Scholar
• Lecis D, Sangaletti S, Colombo MP, Chiodoni C. Immune checkpoint ligand reverse signaling: looking back to go forward in cancer therapy. Cancers (Basel). 2019;11:5. doi:10.3390/cancers11050624
   Web of Science ®Google Scholar
• Ershler WB, Longo DL. Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst. 1997;89(20):1489–1497. doi:10.1093/jnci/89.20.14899337345
   PubMedGoogle Scholar
• An C, Jing W, Zhang Y, et al. Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer. Future Oncol. 2017;13(13):1149–1158. doi:10.2217/fon-2016-046728326834
   PubMed Web of Science ®Google Scholar